Virbagen Omega


interferon (omega)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 07/10/2021

Authorisation details

Product details
Virbagen Omega
Agency product number
Active substance
recombinant omega interferon of feline origin
International non-proprietary name (INN) or common name
interferon (omega)
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Virbac S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

1ère Avenue 2065 M - L.I.D.
06516 Carros Cedex

Product information

07/10/2021 Virbagen Omega - EMEA/V/C/000061 - IG1409/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication


Reduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.


Treatment of cats infected with feline leukaemia virus (FeLV) and / or feline immunodeficiency virus (FIV), in non-terminal clinical stages, from the age of nine weeks. In a field study conducted, it was observed that there was:

  • a reduction of clinical signs during the symptomatic phase (four months);
  • a reduction of mortality:
    • in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;
    • in non-anaemic cats, mortality rate of 50% in cats infected by FeLV was reduced by 20% following treatment with interferon. In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.

Assessment history

How useful was this page?

Add your rating
4 ratings